LSD1 inhibitors has been shown to exert anticancer effects against SCLC in vitro and in vivo through inhibition of the interaction between LSD1 and SNAG domain proteins; insulinoma-associated protein 1 (INSM1) or Growth factor independence 1B (38, 39). This evidence concerns the gene KDM1A and small cell lung carcinoma.